Table 2.
The Chi-square analysis of the clinicopathologic variables between the high-AAPR and low-AAPR groups in the training cohort.
| Variables | AAPR > 0.439, n (%) | AAPR ≤ 0.439, n (%) | P value | |
|---|---|---|---|---|
| Total | 117 (31.5) | 255 (68.5) | ||
| Age, years | ≤52 | 51 (43.6) | 135 (52.9) | 0.094 |
| >52 | 66 (56.4) | 120 (47.1) | ||
| Gender | Male | 110 (94.0) | 238 (93.3) | 0.803 |
| Female | 7 (6.0) | 17 (6.7) | ||
| Ascites | Yes | 18 (15.4) | 59 (23.1) | 0.087 |
| No | 99 (84.6) | 196 (76.9) | ||
| Laboratory parameters | ||||
| AFP, ng/dL | >400 | 47 (40.2) | 126 (49.4) | 0.097 |
| ≤400 | 70 (59.8) | 129 (50.6) | ||
| BUN, mmol/L | >8.9 | 3 (2.6) | 8 (3.1) | 0.762 |
| ≤8.9 | 114 (97.4) | 247 (96.9) | ||
| ALB, g/L | >36 | 107 (91.5) | 139 (54.5) | <0.001 |
| ≤36 | 10 (8.5) | 116 (45.5) | ||
| ALP, U/L | >200 | 0 (0) | 51 (20.0) | <0.001 |
| ≤200 | 117 (100.0) | 204 (80.0) | ||
| Child-Pugh grade | A | 104 (88.9) | 182 (71.4) | <0.001 |
| B | 13 (11.1) | 73 (28.6) | ||
| TNM stage | III-IV | 80 (68.4) | 204 (80.0) | 0.014 |
| I-II | 37 (31.6) | 51 (20.0) | ||
| T category | T3-4 | 79 (67.5) | 202 (79.2) | 0.015 |
| T1-2 | 38 (32.5) | 53 (20.8) | ||
| N category | N0 | 105 (89.7) | 196 (76.9) | 0.003 |
| N1 | 12 (10.3) | 59 (23.1) | ||
| M category | M0 | 112 (95.7) | 230 (90.2) | 0.069 |
| M1 | 5 (4.3) | 25 (9.8) | ||
| PVTT | Yes | 29 (24.8) | 131 (51.4) | <0.001 |
| No | 88 (75.2) | 124 (48.6) | ||
| Survival rates (%) | 3-months | 99.1 | 87.5 | <0.001 |
| 6-months | 94.0 | 76.5 | <0.001 | |
| 1-year | 85.5 | 60.8 | <0.001 | |
| 2-year | 71.8 | 46.7 | <0.001 | |
HCC: hepatocellular carcinoma; TACE: transcatheter arterial chemoembolization; AFP: alpha fetoprotein; BUN: blood urea nitrogen; ALB: albumin; ALP: alkaline phosphatase; AAPR: albumin-to-alkaline phosphatase ratio; TNM: tumour-node-metastasis; PVTT: portal vein tumour thrombus.